- Home
- OCX
OCX
Oncocyte Corporation
as 03-27-2025 3:41pm EST
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $4.42 | AVG Volume (30 days): | 118.6K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.92 - $4.75 | Next Earning Date: | 03-24-2025 |
| Revenue: | $1,881,000 | Revenue Growth: | 25.15% |
| Revenue Growth (this year): | -44.6% | Revenue Growth (next year): | 452.50% |
Stock Insider Trading Activity of Oncocyte Corporation (OCX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SMITH PATRICK W | OCX | 10% Owner | Feb 7 '25 | Buy | $2.05 | 1,077,600 | $2,209,080.00 | 2,872,671 | |
| James Andrea S. | OCX | Chief Financial Officer | Feb 7 '25 | Buy | $2.05 | 97,561 | $200,000.05 | 151,231 | |
| BROADWOOD PARTNERS, L.P. | OCX | 10% Owner | Feb 6 '25 | Buy | $1.03 | 5,165,695 | $10,589,674.75 | 11,410,100 | |
| SMITH PATRICK W | OCX | 10% Owner | Jan 31 '25 | Buy | $2.01 | 915 | $1,839.40 | 2,872,671 | |
| SMITH PATRICK W | OCX | 10% Owner | Jan 29 '25 | Buy | $2.01 | 4,198 | $8,437.98 | 2,872,671 | |
| SMITH PATRICK W | OCX | 10% Owner | Jan 13 '25 | Buy | $2.10 | 16,055 | $34,114.42 | 2,872,671 |
Latest Oncocyte Corporation News
OCX Breaking Stock News: Dive into OCX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
GlobeNewswire
9 days ago
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Insider Monkey
a month ago
OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying Recently
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 02/13/2025
TipRanks
a month ago
OncoCyte prices $29.1M equity offering
GlobeNewswire
a month ago
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
GlobeNewswire
2 months ago
Oncocyte Prices $29.1 Million Equity Offering
Simply Wall St.
2 months ago
Insider Stock Buying Reaches US$508.4k On OncoCyte
Compare OCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCX Oncocyte Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.